Work Here?
Overview
Bimeda is a global veterinary pharmaceutical company that develops, manufactures, markets, and distributes animal health products. Its offerings range from medicines to wellness products for veterinarians, farmers, and animal health professionals, all aimed at improving animal health and wellbeing. The company supports its products with science from eight research and development laboratories, and distributes them in more than 80 countries. It grows through a mix of organic expansion and acquisitions, expanding its geographic reach and product lineup. A core focus is sustainability, integrating environmental and social responsibility into product development, delivery, and daily operations. Bimeda’s goal is to positively impact customers, communities, and the environment through collaboration, continuous improvement, and reliable animal health solutions.
About Bimeda
Industries
Industrial & Manufacturing
Biotechnology
Healthcare
Company Size
1-10
Company Stage
N/A
Total Funding
N/A
Headquarters
N/A
Founded
N/A
Get referred to Bimeda
See people who can refer or advise you
Simplify's Take
What believers are saying
- GASTROBIM launched nationwide in May 2026, expanding Bimeda's fastest-growing omeprazole franchise.
- Enhanced BOVitalize Plus debuted May 2026, strengthening cattle nutrition and performance sales.
- Dr. Chris Olsen joined swine technical services, supporting autogenous vaccines and pharmaceuticals.
What critics are saying
- GASTROBIM directly attacks Zoetis GastroGard, inviting immediate price compression in 2026.
- Pomona integration creates execution risk, and Dechra supply handoffs can disrupt 2026 shipments.
- If GASTROBIM stalls, Zoetis and Elanco keep Bimeda trapped in low-margin generics.
What makes Bimeda unique
- Bimeda's April 2026 Pomona acquisition adds U.S. manufacturing capacity and supply control.
- Its 2026 FDA-approved GASTROBIM matches GastroGard, targeting price-sensitive equine veterinarians.
- Bimeda sells across 80 countries, pairing generic biosimilars with branded livestock support.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
401(k) Retirement Plan
Paid Vacation
Life Insurance
Employee Assistance Program
Paid Holidays
Company News
New treatment for bovine endometritis. 4 Aug 2026 11:00 AM Bimeda UK has launched Bimacure, which it says is the UK's first generic intrauterine cefapirin suspension for cattle, for the treatment of subacute and chronic endometritis. The formulation contains 500mg cefapirin per syringe and is for use in cows at least 14 days after parturition. It is supplied in packs of 10 sets each of syringes, administration catheters and gloves; the catheter and syringe connection have been designed to avoid 'pop offs' at critical moments. The firm says feedback about the product from other markets has been "extremely positive".
Bimeda introduces enhanced BOVitalize Plus. Product now fortified with A. oryzae to support cattle health, digestion and performance. May 19, 2026 Bimeda is proud to announce the launch of its newly enhanced BOVitalize Plus, now fortified with Aspergillus oryzae to deliver an even more comprehensive approach to cattle health, digestion and performance. This advancement builds on the trusted formulation of essential trace minerals and vitamins - selenium, copper, zinc, vitamin A and vitamin E - by adding targeted digestive support designed to help cattle get more from every bite of feed. For producers and veterinarians, the inclusion of A. oryzae represents a significant step forward in rumen efficiency. A oryzae provides enzymatic activity that enhances fiber breakdown, helping cattle maintain intake and digestive consistency during diet transitions, periods of stress or when forage quality declines. By supporting more efficient fiber utilization, the upgraded BOVitalize Plus helps optimize nutrient absorption, stabilize the rumen environment, and promote improved overall performance across all stages of production. This enhancement reflects its commitment to delivering solutions that truly support the challenges cattle face every day," said Dr. Eric Moore, head of technical services North America at Bimeda. "By combining key vitamins and minerals with the proven digestive benefits of Aspergillus oryzae - and refining how the formula performs in suspension - we're offering a more complete, performance-driven supplement designed to keep animals healthy, efficient and moving forward." The improved BOVitalize Plus continues to offer the same convenient oral dosing, eliminating the need for additional injections and reducing labor at the chute. With the added digestive benefits of A. oryzae, the product now delivers an even stronger value proposition for both cow-calf and stocker operations seeking to improve health, consistency and overall productivity. BOVitalize Plus is now available through authorized Bimeda distributors. Bimeda is a leading global manufacturer of animal health products used in more than 80 countries worldwide and is committed to providing innovative solutions that support livestock health, welfare and performance. Feedstuffs is the news source for animal agriculture
Bimeda(r) announces U.S. Availability of gastrobim(tm)(omeprazole) the first and only fda-approved bioequivalent to gastrogard(r)(omeprazole) for Equine Gastric Ulcer treatment. Now available nationwide. Horse owners are encouraged to contact their veterinarian. Bimeda(R), a global leader in animal health solutions, today announced the U.S. launch of GASTROBIM(TM)(omeprazole), the first and only FDA-approved bioequivalent to GastroGard(R)(omeprazole) for the treatment and prevention of recurrence of gastric ulcers in horses and foals four weeks of age and older. This apple-flavored formulation offers veterinarians, trainers, and horse owners a clinically equivalent, high-quality alternative for the effective management of Equine Gastric Ulcer Syndrome (EGUS), addressing a critical need in equine health. Since its initial launch in 2024, GASTROBIM(TM) has rapidly emerged as the fastest-growing omeprazole product in Canada and Europe. Its strong adoption and positive reception among veterinarians and horse owners underscore its proven efficacy in treating and healing gastric ulcers, reinforcing its position as a trusted therapeutic option worldwide. The introduction of GASTROBIM(TM) in the U.S. further expands Bimeda's established equine portfolio, which includes leading brands such as EquiMAX(R)(1.87% ivermectin 14.03% praziquantel), Polyglycan(TM)(hyaluronic acid + chondroitin sulfates C4 & C6 + N-acetyl-D-glucosamine sterile solution), Detomequin(R)(detomidine hydrochloride), and Bimectin(R)(ivermectin paste), and reflects the company's ongoing commitment to delivering innovative, reliable solutions to the equine industry. "We are thrilled to introduce GASTROBIM(TM) to the U.S. market," said Eric Moore, DVM, Bimeda's Head of Technical Services North America. "Gastric ulcers remain one of the most common and performance limiting conditions in horses. Offering a bioequivalent, rigorously tested treatment underscores our commitment to supporting equine health, welfare, and performance at an affordable price." Equine Gastric Ulcer Syndrome (EGUS) affects a significant percentage of performance horses, often leading to reduced appetite, behavioral changes, discomfort, and decreased athletic performance. By introducing a bioequivalent, apple-flavored alternative, Bimeda aims to broaden access to effective treatment options and support improved health and performance outcomes across the equine industry.
People on the move: dr. Chris Olsen. Dr. Chris Olsen has joined Bimeda as their U.S. Swine Technical Service Veterinarian. In this role, he will support the growth of the company's swine autogenous vaccine business and provide technical expertise across its swine pharmaceutical portfolio. He was previously employed by Pharmacosmos. Dr. Olsen's updated contact information is available at aasv.org/directory. Are you on the move? Let Aasv Go know at [email protected].
Bimeda is Hiring for 18 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Bimeda
Industries
Industrial & Manufacturing
Biotechnology
Healthcare
Company Size
1-10
Company Stage
N/A
Total Funding
N/A
Headquarters
N/A
Founded
N/A
Bimeda is Hiring for 18 Jobs on Simplify!
Find jobs on Simplify and start your career today